Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial

被引：0
|
作者：
Shumack, Stephen [1 ]
Blauvelt, Andrew [2 ]
Iversen, Lars [3 ]
McBride, Sandy [4 ]
Gooderham, Melinda [5 ,6 ]
Staubach-Renz, Petra [7 ]
Yamauchi, Paul [8 ,9 ]
Staelens, Fabienne [10 ]
Vanvoorden, Veerle [10 ]
White, Katy [10 ]
Gisondi, Paolo [11 ]
机构：
[1] St George Dermatol & Skin Canc Ctr, Kogarah, NSW, Australia
[2] Oregon Med Res Ctr, Portland, OR USA
[3] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark
[4] Royal Free London NHS Fdn Trust, London, England
[5] Queens Univ, SKiN Ctr Dermatol, Peterborough, ON, Canada
[6] Prob Med Res, Peterborough, ON, Canada
[7] Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, Mainz, Germany
[8] Dermatol Inst & Skin Care Ctr, Santa Monica, CA USA
[9] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA USA
[10] UCB Pharma, Brussels, Belgium
[11] Univ Hosp Verona, Verona, Italy
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [21] Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study
    Nina Magnolo
    Külli Kingo
    Vivian Laquer
    John Browning
    Adam Reich
    Jacek C. Szepietowski
    Deborah Keefe
    Philemon Papanastasiou
    Weibin Bao
    Pascal Forrer
    Manmath Patekar
    Pediatric Drugs, 2022, 24 : 377 - 387
  • [22] Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study
    Magnolo, Nina
    Kingo, Kulli
    Laquer, Vivian
    Browning, John
    Reich, Adam
    Szepietowski, Jacek C.
    Keefe, Deborah
    Papanastasiou, Philemon
    Bao, Weibin
    Forrer, Pascal
    Patekar, Manmath
    PEDIATRIC DRUGS, 2022, 24 (04) : 377 - 387
  • [23] Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
    Reich, Kristian
    Armstrong, April W.
    Langley, Richard G.
    Flavin, Susan
    Randazzo, Bruce
    Li, Shu
    Hsu, Ming-Chun
    Branigan, Patrick
    Blauvelt, Andrew
    LANCET, 2019, 394 (10201): : 831 - 839
  • [24] Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial
    Blauvelt, Andrew
    Wu, Jashin J.
    Reich, Kristian
    Gooderham, Melinda
    Lebwohl, Mark
    White, Katy
    Cross, Nancy
    Cioffi, Christopher
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB139 - AB139
  • [25] Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
    Blauvelt, Andrew
    Papp, Kim A.
    Merola, Joseph F.
    Gottlieb, Alice B.
    Cross, Nancy
    Madden, Cynthia
    Wang, Maggie
    Cioffi, Christopher
    Griffiths, Christopher E. M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) : 1367 - 1374
  • [26] Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial
    Blauvelt, Andrew
    Lomaga, Mark
    Burge, Russel
    Zhu, Baojin
    Shen, Wei
    Shrom, David
    Dossenbach, Martin
    Pinter, Andreas
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (02) : 141 - 146
  • [27] Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study
    Papp, Kim
    Warren, Richard B.
    Green, Lawrence
    Reich, Kristian
    Langley, Richard G.
    Paul, Carle
    Asahina, Akihiko
    Johnson, Lynne
    Arora, Vipin
    Osuntokun, Olawale
    Lebwohl, Mark
    LANCET RHEUMATOLOGY, 2023, 5 (09): : E542 - E552
  • [28] Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
    Kokolakis, Georgios
    Warren, Richard B.
    Strober, Bruce
    Blauvelt, Andrew
    Puig, Luis
    Morita, Akimichi
    Gooderham, Melinda
    Koerber, Andreas
    Vanvoorden, Veerle
    Wang, Maggie
    de Cuyper, Dirk
    Madden, Cynthia
    Gomez, Natalie Nunez
    Lebwohl, Mark
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (03) : 330 - 340
  • [29] BIMEKIZUMAB EFFICACY IN HIGH-IMPACT AREAS FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: POOLED RESULTS THROUGH TWO YEARS FROM THE BE SURE AND BE RADIANT PHASE 3 TRIALS
    Merola, J. F.
    Gottlieb, A. B.
    Morita, A.
    Carrascosa, J. M.
    Elewski, B.
    Tilt, N.
    Wiegratz, S.
    Wixted, K.
    Mrowietz, U.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1766 - 1767
  • [30] Bimekizumab response maintenance in high-impact areas in patients with moderate to severe plaque psoriasis: Pooled results through 96 weeks of the BE SURE, BE READY, and BE RADIANT phase 3/3b trials
    Merola, Joseph F.
    Warren, Richard B.
    Han, George
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB24 - AB24
12345